Susquehanna International Group, LLP X4 Pharmaceuticals, Inc Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.54 - $0.86 $12,366 - $19,694	-22,900 Reduced 14.34%	136,800 $91,000
Q2 2024 Aug 15, 2024	BUY	$0.58 - $1.47 $21,576 - $54,684	37,200 Added 30.37%	159,700 $92,000
Q1 2024 May 07, 2024	BUY	$0.72 - $1.46 $67,608 - $137,094	93,900 Added 328.32%	122,500 $170,000
Q4 2023 Feb 14, 2024	BUY	$0.61 - $0.99 $5,368 - $8,712	8,800 Added 44.44%	28,600 $24,000
Q3 2023 Nov 14, 2023	SELL	$1.03 - $2.02 $65,199 - $127,866	-63,300 Reduced 76.17%	19,800 $21,000
Q2 2023 Aug 11, 2023	BUY	$0.82 - $2.49 $58,712 - $178,284	71,600 Added 622.61%	83,100 $161,000
Q1 2023 May 16, 2023	SELL	$0.8 - $1.22 $68,400 - $104,310	-85,500 Reduced 88.14%	11,500 $10,000
Q4 2022 Feb 14, 2023	BUY	$0.69 - $2.21 $66,930 - $214,370	97,000 New	97,000 $96,000
Q4 2021 Feb 14, 2022	SELL	$1.9 - $5.6 $8,360 - $24,640	-4,400 Reduced 8.38%	48,100 $110,000
Q3 2021 Nov 15, 2021	BUY	$4.53 - $6.45 $237,825 - $338,625	52,500 New	52,500 $278,000

104

100M

213K

50.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $41.9M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.